Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent

References

• Oliver FJ, Menissier-de Murcia J, de Murcia G. Poly(ADP-ribose) polymerase in the cellular response to DNA damage, apoptosis and disease. Am J Hum Genet 1999; 64:1282 - 1288; PMID: 10205258; http://dx.doi.org/10.1086/302389
   PubMed Web of Science ®Google Scholar
• Yélamos J, Schreiber V, Dantzer F. Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol Med 2008; 14:169 - 178; PMID: 18353725; http://dx.doi.org/10.1016/j.molmed.2008.02.003
   PubMed Web of Science ®Google Scholar
• Rouleau M, Aubin RA, Poirier GG. Poly(ADP-ribosyl) ated chromatin domains: access granted. J Cell Sci 2004; 117:815 - 825; PMID: 14963022; http://dx.doi.org/10.1242/jcs.01080
   PubMed Web of Science ®Google Scholar
• Pleschke JM, Kleczkowska HE, Strohm M, Althaus FR. Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins. J Biol Chem 2000; 275:40974 - 40980; PMID: 11016934; http://dx.doi.org/10.1074/jbc.M006520200
   PubMed Web of Science ®Google Scholar
• Prasad R, Lavrik OI, Kim SJ, Kedar P, Yang XP, Vande Berg BJ, et al. DNA polymerasebeta-mediated long patch base excision repair. Poly(ADP-ribose)polymerase-1 stimulates strand displacement DNA synthesis. J Biol Chem 2001; 276:32411 - 32414; PMID: 11440997; http://dx.doi.org/10.1074/jbc.C100292200
   PubMed Web of Science ®Google Scholar
• Yang YG, Cortes U, Patnaik S, Jasin M, Wang ZQ. Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks. Oncogene 2004; 23:3872 - 3882; PMID: 15021907; http://dx.doi.org/10.1038/sj.onc.1207491
   PubMed Web of Science ®Google Scholar
• Liu X, Shi Y, Guan R, Donawho C, Luo Y, Palma J, et al. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. Mol Cancer Res 2008; 6:1621 - 1629; PMID: 18922977
   PubMed Web of Science ®Google Scholar
• Veuger SJ, Curtin NJ, Smith GC, Durkacz BW. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene 2004; 23:7322 - 7329; PMID: 15286704; http://dx.doi.org/10.1038/sj.onc.1207984
   PubMed Web of Science ®Google Scholar
• Hochegger H, Dejsuphong D, Fukushima T, Morrison C, Sonoda E, Schreiber V, et al. Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J 2006; 25:1305 - 1314; PMID: 16498404; http://dx.doi.org/10.1038/sj.emboj.7601015
   PubMed Web of Science ®Google Scholar
• Hawtin RE, Stockett DE, Wong OK, Lundin C, Helleday T, Fox JA. Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks. Oncotarget 2010; 1:606 - 619; PMID: 21317456
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917 - 921; PMID: 15829967; http://dx.doi.org/10.1038/nature03445
   PubMed Web of Science ®Google Scholar
• Boss DS, Beijnen JH, Schellens JH. Inducing Synthetic Lethality using PARP Inhibitors. Curr Clin Pharmacol 2010; 5:192 - 195; PMID: 20406170; http://dx.doi.org/10.2174/157488410791498798
   PubMedGoogle Scholar
• Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 2011; 10:1192 - 1199; PMID: 21487248; http://dx.doi.org/10.4161/cc.10.8.15273
   PubMed Web of Science ®Google Scholar
• Plummer R, Woll P, Fyfe D, Boddy AV, Griffin M, Hewitt P, et al. A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies. Clin Cancer Res 2008; 14:8288 - 8294; PMID: 19088046; http://dx.doi.org/10.1158/1078-0432.CCR-08-0471
   PubMed Web of Science ®Google Scholar
• Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008; 14:7917 - 7923; PMID: 19047122; http://dx.doi.org/10.1158/1078-0432.CCR-08-1223
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12:852 - 861; PMID: 21862407; http://dx.doi.org/10.1016/S1470-2045(11)70214-5
   PubMed Web of Science ®Google Scholar
• Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004; 73:39 - 85; PMID: 15189136; http://dx.doi.org/10.1146/annurev.biochem.73.011303.073723
   PubMed Web of Science ®Google Scholar
• Joerger AC, Fersht AR. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 2007; 26:2226 - 2242; PMID: 17401432; http://dx.doi.org/10.1038/sj.onc.1210291
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307 - 310; PMID: 11099028; http://dx.doi.org/10.1038/35042675
   PubMed Web of Science ®Google Scholar
• Smith ML, Seo YR. p53 regulation of DNA excision repair pathways. Mutagenesis 2002; 17:149 - 156; PMID: 11880544; http://dx.doi.org/10.1093/mutage/17.2.149
   PubMed Web of Science ®Google Scholar
• Arias-Lopez C, Lazaro-Trueba I, Kerr P, Lord CJ, Dexter T, Iravani M, et al. p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep 2006; 7:219 - 224; PMID: 16322760; http://dx.doi.org/10.1038/sj.embor.7400587
   PubMed Web of Science ®Google Scholar
• Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282:1497 - 1501; PMID: 9822382; http://dx.doi.org/10.1126/science.282.5393.1497
   PubMed Web of Science ®Google Scholar
• Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13:2728 - 2737; PMID: 17473206; http://dx.doi.org/10.1158/1078-0432.CCR-06-3039
   PubMed Web of Science ®Google Scholar
• Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009; 27:2705 - 2711; PMID: 19364967; http://dx.doi.org/10.1200/JCO.2008.19.7681
   PubMed Web of Science ®Google Scholar
• Yang SX, Kummar S, Steinberg SM, Murgo AJ, Gutierrez M, Rubinstein L, et al. Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biol Ther 2009; 8:2004 - 2009; PMID: 19823047; http://dx.doi.org/10.4161/cbt.8.21.9917
   PubMed Web of Science ®Google Scholar
• Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, et al. Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas. Cancer Res 2011; 71:5626 - 5634; PMID: 21795476; http://dx.doi.org/10.1158/0008-5472.CAN-11-1227
   PubMed Web of Science ®Google Scholar
• Imbriano C, Gurtner A, Cocchiarella F, Di Agostino S, Basile V, Gostissa M, et al. Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol Cell Biol 2005; 25:3737 - 3751; PMID: 15831478; http://dx.doi.org/10.1128/MCB.25.9.3737-51.2005
   PubMed Web of Science ®Google Scholar
• Yu Q, La Rose J, Zhang H, Takemura H, Kohn KW, Pommier Y. UCN-01 inhibits p53 upregulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res 2002; 62:5743 - 5748; PMID: 12384533
   PubMed Web of Science ®Google Scholar
• Furuta T, Hayward RL, Meng LH, Takemura H, Aune GJ, Bonner WM, et al. p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine. Oncogene 2006; 25:2839 - 2849; PMID: 16407843; http://dx.doi.org/10.1038/sj.onc.1209313
   PubMed Web of Science ®Google Scholar
• Rouault JP, Falette N, Guehenneux F, Guillot C, Rimokh R, Wang Q, et al. Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 1996; 14:482 - 486; PMID: 8944033; http://dx.doi.org/10.1038/ng1296-482
   PubMed Web of Science ®Google Scholar
• Velasco-Miguel S, Buckbinder L, Jean P, Gelbert L, Talbott R, Laidlaw J, et al. PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes. Oncogene 1999; 18:127 - 137; PMID: 9926927; http://dx.doi.org/10.1038/sj.onc.1202274
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303:1010 - 1014; PMID: 14963330; http://dx.doi.org/10.1126/science.1092734
   PubMed Web of Science ®Google Scholar
• Fan J, Wray J, Meng X, Shen Z. BCCIP is required for the nuclear localization of the p21 protein. Cell Cycle 2009; 8:3019 - 3024; PMID: 19713748; http://dx.doi.org/10.4161/cc.8.18.9622
   PubMed Web of Science ®Google Scholar
• Eymin B, Claverie P, Salon C, Leduc C, Col E, Brambilla E, et al. p14ARF activates a Tip60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress. Mol Cell Biol 2006; 26:4339 - 4350; PMID: 16705183; http://dx.doi.org/10.1128/MCB.02240-05
   PubMed Web of Science ®Google Scholar
• Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408:433 - 439; PMID: 11100718; http://dx.doi.org/10.1038/35044005
   PubMed Web of Science ®Google Scholar
• Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget 2011; 2:222 - 233; PMID: 21447859
   PubMed Web of Science ®Google Scholar
• Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001; 20:1803 - 1815; PMID: 11313928; http://dx.doi.org/10.1038/sj.onc.1204252
   PubMed Web of Science ®Google Scholar
• Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1:315 - 322; PMID: 20049735; http://dx.doi.org/10.1002/emmm.200900041
   PubMed Web of Science ®Google Scholar
• Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006; 5:2606 - 2612; PMID: 17088437; http://dx.doi.org/10.1158/1535-7163.MCT-06-0433
   PubMed Web of Science ®Google Scholar
• Yang SX, Simon RM, Tan AR, Nguyen D, Swain SM. Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. Clin Cancer Res 2005; 11:6226 - 6232; PMID: 16144925; http://dx.doi.org/10.1158/1078-0432.CCR-05-0270
   PubMed Web of Science ®Google Scholar
• Pavlidis P, Qin J, Arango V, Mann JJ, Sibille E. Using the gene ontology for microarray data mining: a comparison of methods and application to age effects in human prefrontal cortex. Neurochem Res 2004; 29:1213 - 1222; PMID: 15176478; http://dx.doi.org/10.1023/B:NERE.0000023608.29741.45
   PubMed Web of Science ®Google Scholar
• Yang SX, Steinberg SM, Nguyen D, Wu TD, Modrusan Z, Swain SM. Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res 2008; 14:5893 - 5899; PMID: 18794102; http://dx.doi.org/10.1158/1078-0432.CCR-07-4762
   PubMed Web of Science ®Google Scholar
• Simon R. Analysis of DNA microarray expression data. Best Pract Res Clin Haematol 2009; 22:271 - 282; PMID: 19698933; http://dx.doi.org/10.1016/j.beha.2009.07.001
   PubMed Web of Science ®Google Scholar
• Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104:263 - 269; PMID: 10430607; http://dx.doi.org/10.1172/JCI6863
   PubMed Web of Science ®Google Scholar
• Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 2003; 278:28045 - 28051; PMID: 12732644; http://dx.doi.org/10.1074/jbc.M300554200
   PubMed Web of Science ®Google Scholar